FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease
Links shared publicly online about this topic.
- 470total visits
FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease
View full resource at drugs.com
Tags: COPD, Disease and Condition, Drug, FDA, Pulmonology, disease
Most Recently Shared on March 1, 2011 at 11:13 pm By:
FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease: SILVER SPRING, Md., March 1, 2011 /P... http://bit.ly/igBEvJ #drug
FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for the Treatment of Patients with Chronic Obstructive Pulmonary Disease
drugs.com — “Combivent Respimat (albuterol and ipratropium bromide) is used to treat chronic obstructive pulmonary disease. Includes Combivent Respimat side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on October 11, 2011 at 12:07 am By:
FDA Approves Combivent Respimat (ipratropium bromide and albuterol) Inhalation Spray for COPD - http://t.co/3UJWkUpF
FDA Approves Arcapta Neohaler To Treat Chronic Obstructive Pulmonary Disease - QualityPoint Technologies
qualitypointtech.net — “The U.S. Food and Drug Administration approved Arcapta Neohaler (indacaterol inhalation powder) for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm...” View full resource at qualitypointtech.net
Most Recently Shared on July 3, 2011 at 8:45 am By:
FDA Approves Arcapta Neohaler To Treat Chronic Obstructive Pulmonary Disease: The U.S. Food and Drug Administratio... http://bit.ly/iCpKuD
Medicine and Technology [part of HCPLive]: FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease
medicineandtechnology.com — “Medicine and Technology [part of HCPLive]: FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease” View full resource at medicineandtechnology.com
Most Recently Shared on July 3, 2011 at 1:05 am By:
Joseph Kim, MD, MPH Doctor and Physician
FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease http://goo.gl/fb/BMG9q
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms
rttnews.com — “Novartis AG (NVS), Friday announced that the US Food and Drug Administration has approved once-daily Arcapta Neohaler (indacaterol inhalation powder) 75 mcg for the long-term maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.” View full resource at rttnews.com
Most Recently Shared on July 2, 2011 at 2:30 am By:
Michael Blaiss, MD Doctor, Allergist, and Physician
Novartis Announces FDA Approval For Arcapta To Treat COPD Symptoms, once a day bronchodilator - http://goo.gl/cd9hS
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease
drugs.com — “Arcapta Neohaler (indacaterol inhalation powder) is used to treat chronic obstructive pulmonary disease (COPD). Includes Arcapta Neohaler side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 2, 2011 at 12:11 am By:
Drugs and Devices OW OW Health
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease: The U.S. Food and Drug Admin... http://bit.ly/jIhfVN #drug
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease
drugs.com — “Arcapta Neohaler (indacaterol inhalation powder) is used to treat chronic obstructive pulmonary disease (COPD). Includes Arcapta Neohaler side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on July 1, 2011 at 11:39 pm By:
FDA Approves Arcapta Neohaler to treat Chronic Obstructive Pulmonary Disease - http://bit.ly/mOT339
Forest, Nycomed Win FDA Approval for Daliresp Lung Medicine - Bloomberg
bloomberg.com — “Forest Laboratories Inc. and Nycomed A/S won U.S. approval for the Daliresp drug to treat chronic obstructive pulmonary disease, also known as smokers--™ cough, after regulators asked for more information on the product last year.” View full resource at bloomberg.com
Most Recently Shared on March 2, 2011 at 2:55 pm By:
Marya Zilberberg, MD Doctor, Internist, and Physician
Thoughts on roflumilast FDA approval for COPD, despite ad comm 10-5 vote against? http://bloom.bg/fCJFvh
FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease
drugs.com — “Daliresp (roflumilast) is used to treat chronic obstructive pulmonary disease (COPD). Includes Daliresp side effects, interactions and indications.” View full resource at drugs.com
Most Recently Shared on March 1, 2011 at 11:03 pm By:
FDA Approves Daliresp to Treat Chronic Obstructive Pulmonary Disease - http://bit.ly/evS3ws
COPD Maintenance Drug Approved by FDA | ThirdAge
thirdage.com — “The FDA approved the first oral anti-inflammatory treatment for chronic obstructive pulmonary disease. The once-a-day tablet, DalirespTM (roflumilast), helps reduce lung functions for OCPD patients who experience breathlessness, chronic cough and” View full resource at thirdage.com
Most Recently Shared on March 1, 2011 at 9:00 pm By:
COPD Maintenance Drug Approved by FDA http://bit.ly/eJUK5k
FDA approves Forest Labs' Daliresp to treat COPD
news-medical.net — “Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.” View full resource at news-medical.net
Most Recently Shared on March 1, 2011 at 11:37 am By:
Osteoporosis News: FDA approves Forest Labs' Daliresp to treat COPD: Forest Laboratories, Inc. announced today t... http://bit.ly/gN2zHY
Advertisement
